<SEC-DOCUMENT>0001213900-25-108761.txt : 20251112
<SEC-HEADER>0001213900-25-108761.hdr.sgml : 20251112
<ACCEPTANCE-DATETIME>20251112080815
ACCESSION NUMBER:		0001213900-25-108761
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20251112
FILED AS OF DATE:		20251112
DATE AS OF CHANGE:		20251112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALTERITY THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001131343
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-49843
		FILM NUMBER:		251469114

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		LEVEL 3, 460 BOURKE STREET
		CITY:			MELBOURNE
		PROVINCE COUNTRY:   	C3
		BUSINESS PHONE:		61 3 9349 4906

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		LEVEL 3, 460 BOURKE STREET
		CITY:			MELBOURNE
		PROVINCE COUNTRY:   	C3

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRANA BIOTECHNOLOGY LTD
		DATE OF NAME CHANGE:	20010105
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0265246-6k_alterity.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>



<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0; font-size: 10pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
6-K</B></FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-163</B></FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the month of November 12, 2025</B></FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alterity
Therapeutics Limited</B></FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Registrant)</FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Level 14, 350 Collins Street,
Melbourne, Victoria 3000 Australia</B></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of Principal Executive Office)</FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</B></FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F &#9744;</FONT></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></p>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>This
Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. <A HREF="http://www.sec.gov/Archives/edgar/data/1131343/000121390020040485/ea130838-s8_alteritytherape.htm">333-251073</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1131343/000121390020027969/ea127207-s8_alteritytherap.htm">333-248980</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1131343/000114420418063081/tv508429_s-8.htm">333-228671</A>)
and our Registration Statements on Form F-3 (Files No. <A HREF="http://www.sec.gov/Archives/edgar/data/1131343/000101376223000033/ea185947-f3_alteritytherape.htm">333-274816</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1131343/000121390020044324/ea132148-f3_alteritytherape.htm">333-251647</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1131343/000114420419025615/tv521271_f3.htm">333-231417</A>
and <A HREF="http://www.sec.gov/Archives/edgar/data/1131343/000121390020036934/ea129831-f3_alteritytherap.htm">333-250076</A>)</B></FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&nbsp;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ALTERITY
THERAPEUTICS LIMITED</B></FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a
development stage enterprise)</B></FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following exhibits are submitted:</FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></p>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%">99.1</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 90%"><A HREF="ea026524601ex99-1_alterity.htm">Alterity to Present at the Bell Potter Healthcare Conference</A></TD></TR>
  </TABLE>










<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SIGNATURE</U></B></FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
   <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Alterity Therapeutics Limited</B></FONT></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 60%">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; width: 4%">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; width: 36%">&nbsp;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Geoffrey
    P. Kempler</FONT></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Geoffrey P. Kempler</FONT></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chairman</FONT></td></tr>
   </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-transform: none; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
November 12, 2025</FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea026524601ex99-1_alterity.htm
<DESCRIPTION>ALTERITY TO PRESENT AT THE BELL POTTER HEALTHCARE CONFERENCE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0; margin-left: 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>Alterity Therapeutics to Present at the Bell
Potter Healthcare Virtual Conference</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>MELBOURNE,
AUSTRALIA AND SAN FRANCISCO, USA &ndash; 12 November 2025:</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">Alterity
Therapeutics</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">(ASX: ATH, NASDAQ: ATHE) (&ldquo;Alterity&rdquo; or &ldquo;the
Company&rdquo;), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced&nbsp;
that David Stamler, M.D., Chief Executive Officer of Alterity, will deliver a corporate update at the Bell Potter Healthcare Conference,
a virtual event showcasing Australia&rsquo;s best healthcare companies.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><B><U>Presentation details</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">AUSTRALIA PARTICIPANTS:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.5in">Date:</TD>
    <TD>Wednesday, 19 November 2025</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Time:</TD>
    <TD> 1:30 p.m. AEDT (Sydney/Melbourne)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">UNITED STATES PARTICIPANTS:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.5in">Date:</TD>
    <TD>Tuesday, 18 November 2025</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Time:</TD>
    <TD>6:30 p.m. Pacific Time</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD></TD>
    <TD>9:30 p.m. Eastern Time</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Current
and interested shareholders can register for the webcast here:</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">Bell
Potter | Healthcare 2025 (EXT)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><B>About Alterity Therapeutics Limited </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Alterity Therapeutics is a clinical stage biotechnology
company dedicated to creating an alternate future for people living&nbsp;with neurodegenerative diseases. The Company is initially focused
on developing disease modifying therapies in Parkinson&rsquo;s disease and related disorders. Alterity has demonstrated clinically meaningful
efficacy for its lead asset, ATH434, in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with Multiple
System Atrophy (MSA), a rare and rapidly progressive Parkinsonian disorder. ATH434 recently reported positive data in its open label Phase
2 clinical trial in advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to
treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California,
USA. For further information please visit the Company&rsquo;s website at www.alteritytherapeutics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>Authorisation &amp; Additional information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">This announcement was authorized by David Stamler, CEO
of Alterity Therapeutics Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>Investors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Remy Bernarda</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Investor Relations Advisory Solutions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">ir@alteritytx.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">+1 (415) 203-6386</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>Media</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Casey McDonald</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Tiberend Strategic Advisors, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">cmcdonald@tiberend.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">+1 (646) 577-8520</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><I>This press release contains &ldquo;forward-looking
statements&rdquo; within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.
The Company has tried to identify such forward-looking statements by use of such words as &ldquo;expects,&rdquo; &ldquo;intends,&rdquo; &ldquo;hopes,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;could,&rdquo; &ldquo;may,&rdquo; &ldquo;evidences&rdquo; and &ldquo;estimates,&rdquo; and
other similar expressions, but these words are not the exclusive means of identifying such statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><I>Important factors that could cause
actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled &ldquo;Risk
Factors&rdquo; in the Company&rsquo;s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on
Form 6-K, including, but not limited to the following: statements relating to the Company&rsquo;s drug development program, including, but not
limited to the initiation, progress and outcomes of clinical trials of the Company&rsquo;s drug development program, including, but not limited
to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not
limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval,
production and marketing of the Company&rsquo;s drug components, including, but not limited to, ATH434, the ability of the Company to
procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company&rsquo;s drug
compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent
protection for the Company&rsquo;s intellectual property or trade secrets, the uncertainty of successfully enforcing the Company&rsquo;s patent
rights and the uncertainty of the Company freedom to operate.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><I>Any forward-looking statement made
by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made.
We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  V -T# 2(  A$! Q$!_\0
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M]SL335T%>/?'KQ-]DT:T\/0/B6\;SIP#TC4\#\6_]!KU]W2*-I'8*B@LS$\
M#O7RAKEUJ_Q%^(%]=Z/:RW<FXFWC4#Y84("GGCT/U-7!7=P9M>+/AV=$^%VA
M:RL.V\!W7W'.)>4S_N\+^->R?"[Q+_PDW@>SFE?==VH^S7&3R64<'\5P?SKR
M74+/XPZKI\UA?6U[-:SKMDC98<$?A3/@WKD_AKQU/H.H!H5O28'C?C9.A.W/
MZK^(JFKQ W/VA_\ 6:!])O\ V2NN\3V_B>?X<:*WABZ^SS16L;W#;PN8A#R.
M??%<C^T/_K- ^DW_ +)7JUA&\W@&UBC&7?2T51ZDQ"I>D4!\W_#NQ\8WUSJ
M\(W8MY51#<9D5=PR=O4?6O>M9\3W7@;X<VVH:SBYU9(4A*ELB2<CG)';@DX]
M*\B^"WB;2/#.KZLNLWBV8GA0(T@.,J3D' X/-=U\8;<^*/AM9ZQI6^:VAE6Z
MX4@F(J1NQ[9!^E5)7E8$<II?_"VO&UH=:L]3>UM78^4HE$"N!_=4#D9XR?SK
MIOAMX_URX\2S^$?%2YU",-Y<K* VY1DJV.#QR#[=\UP'@^P\$ZIH\:ZMXIU/
M2[Z,$21&4+&>>"AVGC':NQ\$:!X(7XA6\FAZYJ6IW]M$\YD?;Y6,;,$[02?F
M[>E*5M= &_%?QSKOA7QWIZ:?>R+9K;QS26W&V0[VR#QGD "D\-1?%6_U_2M;
MU*:Y72Y[A&F@$JJ!$3S^[[#'XUB_&]0WQ(TL,,@VT0(_[:-7T,    , =!2=
ME%: >)_$/Q?X@TGXJ6&EV&J3064GV?="N,'<^#V[UI?&RV\3G3'NM/N=F@I;
M!;V/>!N8O@<=3U7I7)?%3_DM.F?2U_\ 0Z]6^*T,DWPRUI8U+$1HQ ] ZDG\
M@:>U@/'/AUIGQ!N]'6;PW?\ DZ6+HB2/S57+?+NX(STQ7H7QFU'Q'H-A8ZOH
MFIW%M;[S!<1QXQD\JW(^H_*L'X/>-_#V@^$+FQU._6WN1=M(L;*27#!0-N!S
MR#7K/BK0X_$GAC4-)D _TB(A"?X7'*G\"!1)VEJ@6Q@VOCF-_A./%3NIE2S)
M<>LX^7'XO_.N4^%C^*/%^DWNI:KXAU!8!*(K<H57) )<].G*_K7D*:UJB>&I
M?!(B?,FHB39GG>!MV8_WL'ZBOJ?PKH47AKPQI^DQ ?Z/$ Y'\3GEC^))HDN5
M <EK>D3Z=<G.YXG/R/Z_7WK=\)Z//:;[R?*>8NU4]N.3^5=.0#U -5=3U"/3
M+%[F4%@O 4=S6TL1.I'V=M6>53RZCAZKKWT6OH1.1_;\(R,_9G_]"6L/QKH-
MQJENEW:DO) I!B]1ZCWKE+CQ#?OJXU$2E9%X4#H%],>E>BZ'K$>M:<+E%V.#
MMD7T;';VYJY4ZF'<:B'2KT<8I4GH>3:1H-YK6H"WA0JJG,DC#A!7K5["+7PW
M<0!RPBM&3<W4X3&35](TCSL15W')P,9->9^.O%TL\LVD61*0HQ2=^[D=1]/Y
MU;G/%U$DK)%1I4\%3;;NV=_#;B[\/QVY<J)K4)N7J,KC(KP?7_#M_H>IM:7$
M3,6/[J11D2#MC_"NZ\">,9%GAT6^)=&(2"3NI[*?;^7\O3"JL02 2.1D=*<:
ME3!U&FKIFG)#%04D[-'%?#GPQ=:#I\]S>DI-=[3Y']Q1G&?<YKMJ**X:M1U)
MN<MV=D(*$5%%74;"'5-.N+"YW^1<1F.38Q4E3P1D=*Q/#/@/P_X1N)Y](M7B
MEG0([O*SG:#G STK>O7N8[.9[*&.:Y"DQQR/L5F]"V#C\JYSPIXBUK7[F\%Y
MI-I:6UI/):N\=V9&,J$ @#8/EYZY_"HUL6=57'ZE\,O#&J:\^MSVDRW[R+*9
M(IV3YQC#8!Z\"K,GC33[3Q-JFD:A/:60LXHI(Y)[A4\[>"2 #CI@>O6I]'\2
MMJG@>/Q&;41E[5[CR-^?NYXSCV]*-4 WQ/X(T/Q>;8ZQ!)*;8,(]DK)C.,].
MO05N6MM%96<%K""(H8UC0$YPH&!_*N6\(^+-0\3&*5[;28[9X!,PMM1\Z:/(
M! 9-HQ[\TW7O&&H:=XCFTFRL+"406:W3R7=]Y&06887Y3D_+1KL!7UCX1^$=
M:U&2^FLI89I6W2?9Y2BLQZG'3/TKKM.TRUTO2K?3;:/%K!$(D1CN^4#&"3UJ
M'0=7CU_0;+58HGB2ZB$HC?JN>U8_AWQG'K^MWMA]D:"- TEE,7R+N)7,;.!V
MPP_(@T:@9FI_![P;JETUP=/DMG8Y86TI13_P'D#\*UO#/@'P[X1E>?2K(I<.
MNQII'+N5].>@X'2D\3>)KW1M5TO3K&RM;B:^65@UU<^2B! #UVGKFK/AOQ'_
M ,)!H4NH&V$$L$LL$D:R"12\9P2KCAE/8T[NP%;Q!X \/^)M5AU+4[:62ZA1
M41EF90 "2. ?4FNGKBO!_C34/%+VTAM-)BMY8S(R1:EYEQ&.VZ/8,<X[]ZW1
MK9/C$Z#]G&!8?;/.W?\ 339MQC\<YI:[ 4-8^'_A[7M>BUJ_MI7OHMFQUF90
M-IR.!Q722Q1SQ/%*BO&ZE61AD,#U!%8^@Z[-KVA3W\5JD<R33PI$TG#-&[(,
MMCC.WTXSWK-\.^(]=U?6[ZQN]'LK:&PE\FXECO#(0Y0,-HV#(Y'<4:@9C_!C
MP:VH?:TL[B/#[Q$DY" YSTZX_&N\GF6W@DF?=LC4NVT9. ,\#O66FN%_&,N@
M_9P%CL5N_.W=<N5VXQ[9SFLZ]\2:K/KEWI7A_2H+R2Q5#=S7-SY**S#(1<*Q
M+8Y]!FC5@>5^ /#]]XE^*][XDU+2YK.UAE>Z1)82@+DX0<CDCJ?<5[[6)X@\
M0/X>\+2ZQ<69>2)$+0*XPK,0.6_N@GD^@S3?#&LW>M6DTURNFE58!)-/O1<Q
MN".><#!%-N^H&[4-U:PWML]O.@>-Q@BBBI3MJA-)JS//+CPJZ^(4TY;A=D@+
MAB.0O^-=_I^GV^F6:6ULFU%ZGN3ZFBBNJO5G)13?0X,'AZ=.4W%=;?+0M5PG
MCOPI#<6TVKVQ6*:,;IE/1QZ_6BBHH3E"HG%G3B(1G3:DA? OA&"R@BU>Z*S7
M,B[H@.D8]?K_ "KNJ**5><IU&Y#H0C"FE$****Q-@K)T'0UT--059S-]LOI;
MPY7&TN0=OOC'6BB@"LOA6S;Q%J>KW BN&OHHHQ'+"K"+8",@GUS^E.TKPTFE
M^#(_#BW32*EL]OYY3!^;/./QHHHN!3\,>%K_ ,.^3$VJP7%I%"(1&E@D3L
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<RXNTGNKXQ^9]GMUMXU" @813UY.23S112 __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
